title: Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research.
abstract: With improvements in hematopoietic cell transplant (HCT) outcomes for severe aplastic anemia (SAA), there is a growing population of SAA survivors after HCT. However, there is a paucity of information regarding late effects that occur after HCT in SAA survivors. This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT. A descriptive analysis was conducted of 1718 patients post-HCT for acquired SAA between 1995 and 2006 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The prevalence and cumulative incidence estimates of late effects are reported for 1-year HCT survivors with SAA. Of the HCT recipients, 1176 (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% confidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all <3% and did not increase over time. In contrast, for recipients of URD HCT, the cumulative incidence of developing several late effects exceeded 3% by 5 years: gonadal dysfunction 10.5% (95% CI: 7.3-14.3), growth disturbance 7.2% (95% CI: 4.4-10.7), avascular necrosis 6.3% (95% CI: 3.6-9.7), hypothyroidism 5.5% (95% CI: 2.8-9.0), and cataracts 5.1% (95% CI: 2.9-8.0). Our results indicated that all patients undergoing HCT for SAA remain at risk for late effects, must be counseled about, and should be monitored for late effects for the remainder of their lives.
authors.affiliation: Department of Hematology, Children's Hospital of Orange County, Orange, California, USA.
authors.forename: David
authors.initials: D
authors.lastname: Buchbinder
authors.forename: Diane J
authors.initials: DJ
authors.lastname: Nugent
authors.forename: Ruta
authors.initials: R
authors.lastname: Brazauskas
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Wang
authors.forename: Mahmoud D
authors.initials: MD
authors.lastname: Aljurf
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.forename: Robert
authors.initials: R
authors.lastname: Chow
authors.forename: Christine
authors.initials: C
authors.lastname: Duncan
authors.forename: Lamis K
authors.initials: LK
authors.lastname: Eldjerou
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Hale
authors.forename: Joerg
authors.initials: J
authors.lastname: Halter
authors.forename: Brandon M
authors.initials: BM
authors.lastname: Hayes-Lattin
authors.forename: Jack W
authors.initials: JW
authors.lastname: Hsu
authors.forename: David A
authors.initials: DA
authors.lastname: Jacobsohn
authors.forename: Rammurti T
authors.initials: RT
authors.lastname: Kamble
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Kasow
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Paulette
authors.initials: P
authors.lastname: Mehta
authors.forename: Kasiani C
authors.initials: KC
authors.lastname: Myers
authors.forename: Susan K
authors.initials: SK
authors.lastname: Parsons
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.forename: Joseph
authors.initials: J
authors.lastname: Pidala
authors.forename: Vijay
authors.initials: V
authors.lastname: Reddy
authors.forename: Carmen M
authors.initials: CM
authors.lastname: Sales-Bonfim
authors.forename: Bipin N
authors.initials: BN
authors.lastname: Savani
authors.forename: Adriana
authors.initials: A
authors.lastname: Seber
authors.forename: Mohamed L
authors.initials: ML
authors.lastname: Sorror
authors.forename: Amir
authors.initials: A
authors.lastname: Steinberg
authors.forename: William A
authors.initials: WA
authors.lastname: Wood
authors.forename: Donna A
authors.initials: DA
authors.lastname: Wall
authors.forename: Jacek H
authors.initials: JH
authors.lastname: Winiarski
authors.forename: Lolie C
authors.initials: LC
authors.lastname: Yu
authors.forename: Navneet S
authors.initials: NS
authors.lastname: Majhail
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D016019:Survival Analysis; D017741:Survivors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult